People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...

Additionally, Heymsfield said more data are needed on whether the safety profile of semaglutide 7.2 mg differs from the 2.4 mg dose. Steven B. Heymsfield “The question is if that extra weight ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

Findings showed semaglutide 7.2mg demonstrated a statistically significant and superior weight loss compared with placebo at week 72. Topline data were announced from a phase 3b trial evaluating ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

At baseline, a physical examination and laboratory tests were conducted. An eleven-week semaglutide drug dose titration period was started, and during this period, all participants continued using ...

Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor agonist semaglutide in adults with obesity. The phase 3b STEP UP trial has been ...